Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner
Name
Xie-2011-June-Counterbalancing ang.pdf
Size
429.38 KB
Format
Adobe PDF
Checksum (MD5)
e7c8ceed5817a41320f3a2506141d2cb
Author(s)
Xie, Liang
Duncan, Michael B.
Pahler, Jessica
Sugimoto, Hikaru
Martino, Margot
Lively, Julie
Mundel, Thomas
Soubasakos, Mary
Takeda, Takaaki
Inoue, Masahiro
Date Issued
May 2011
Journal
Proceedings of the National Academy of Sciences
Publisher
Proceedings of the National Academy of Sciences (PNAS)
Citation
Xie, L. et al. “Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner.” Proceedings of the National Academy of Sciences 108.24 (2011): 9939-9944. Web. 2 Feb. 2012.
Version
Final published version
Abstract
Whereas the roles of proangiogenic factors in carcinogenesis are well established, those of endogenous angiogenesis inhibitors (EAIs) remain to be fully elaborated. We investigated the roles of three EAIs during de novo tumorigenesis to further test the angiogenic balance hypothesis, which suggests that blood vessel development in the tumor microenvironment can be governed by a net loss of negative regulators of angiogenesis in addition to the well-established principle of up-regulated angiogenesis inducers. In a mouse model of pancreatic neuroendocrine cancer, administration of endostatin, thrombospondin-1, and tumstatin peptides, as well as deletion of their genes, reveal neoplastic stage-specific effects on angiogenesis, tumor progression, and survival, correlating with endothelial expression of their receptors. Deletion of tumstatin and thrombospondin-1 in mice lacking the p53 tumor suppressor gene leads to increased incidence and reduced latency of angiogenic lymphomas associated with diminished overall survival. The results demonstrate that EAIs are part of a balance mechanism regulating tumor angiogenesis, serving as intrinsic microenvironmental barriers to tumorigenesis.
MIT Department
Harvard University--MIT Division of Health Sciences and Technology
Massachusetts Institute of Technology. Department of Biology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1073/pnas.1105041108
